Where Will Eli Lilly Stock Be in 10 Years?

Is Pfizer Inc. stock gaining market share - 2025 Bull vs Bear & Community Consensus Trade Signals - Naître et grandir

FDA vaccine chief to leave the agency again (PFE:NYSE) - Seeking Alpha

Munich Reinsurance Co Stock Corp in Munich Purchases Shares of 1,584,714 Pfizer Inc. $PFE - MarketBeat

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Neuberger Berman Group LLC Grows Stock Position in Pfizer Inc. $PFE - MarketBeat

First Trust Advisors LP Increases Position in Pfizer Inc. $PFE - MarketBeat

Pfizer Keto Gummy: A Realistic Look at These Low-Carb Supplements [9GJvmC45B7] - Wright State University

American Century Companies Inc. Sells 546,598 Shares of Pfizer Inc. $PFE - MarketBeat

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

🔔 MARKET CLOSE ────────────────────────────── 📊 INDICES: 🔴 S&P 500: -1.33% (6739.96) 🔴 Nasdaq: -1.59% (22387.68) 🔴 Dow Jones: -0.95% (47501.55) 🔴 Russell 2000: -2.33% (2525.30) 💭 Broad-based selloff. Bears took control today. 🔥 HOT STOCKS: 📉 $NVDA: $177.68 (-3.09%) -

How Pfizer and REDCap Cloud Modernized Clinical Data Sharing - Databricks

Noteworthy Friday Option Activity: PFE, CAPR, DIS - Nasdaq

Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive

Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks

Pfizer breaks into obesity market in China with approval for Sciwind-partnered GLP-1 - Fierce Pharma

The week in GRC: Lululemon boardroom fight intensifies as judge approves settlement between SEC and Pfizer - | Governance Intelligence

Pharmalittle: We're reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more - statnews.com

Aplastic Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui - StreetInsider

China approves Pfizer GLP-1 drug for weight loss - PharmaLive

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore

Judge Approves $29M Pfizer Payout In SAC Capital Dispute - Hoodline

Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union

China Clears Weight-Loss Shot As Pfizer Enters Crowded Market

Pfizer gets green light for slimming drug in China - medwatch.com

Pfizer gets obesity drug approval in China shortly after buying local rights - Endpoints News

Pfizer's Sciwind-sourced GLP-1 wins obesity nod in China - FirstWord Pharma

China's clears Pfizer GLP-1 ecnoglutide for weight loss - pharmaphorum

Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus

Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus

Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat

mRNA Therapeutics Market Booming with Rapid Growth Through 2033 | Moderna • BioNTech • CureVac • Pfizer - openPR.com

Alprazolam Market Is Going to Boom | Pfizer • Teva Pharmaceuticals • Mylan • Sandoz - openPR.com

Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat

Pfizer’s Weight-Loss Drug Approved in China — Up Against Generic Rivals - TipRanks

Pfizer’s Xianweiying wins China approval for obesity - grafa.com

Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat

Pfizer secures China nod for obesity drug as generics loom - The Business Times

Pfizer's (PFE.US) weight-loss drug 'Xianweiying' has been approved in China, with a weight reduction of up to 15.1%. - 富途牛牛

China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders

Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg.com

Pfizer Gets Chinese Approval for Weight Loss Drug Xianweiying - Fine Day 102.3

China approves Pfizer GLP-1 drug for weight management By Reuters - Investing.com

China approves Pfizer GLP-1 drug for weight management - Yahoo Finance

China approves Pfizer GLP-1 drug for weight loss - Reuters

China approves Pfizer GLP-1 drug for weight management - TradingView

Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360

Prince Edward cuts ribbon on PFE Express's Mega HQ in Witham - Geo News

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters

Judge Approves Pfizer, SEC Settlement Tied to Insider Trading at Cohen Hedge Fund - Money/ US News

Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS

Mixed options sentiment in Pfizer with shares down 0.39% - TipRanks

Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360

Smart Money Is Betting Big In PFE Options - Benzinga

Pfizer R&D vs. NIH Summer Internship

Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com

Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - Nasdaq

Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat

Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat

Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha

Skeletal Dysplasia Market - Global Forecast 2026-2032: $5.37 Bn Opportunities Driven by Advancing Diagnostic Precision, Integrated Therapies, Evidence Generation, and Equitable Access

Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market

Pfizer Adds AI Executive Layer as Tech Investments Mount - AIM Media House

Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily

Pfizer CEO Albert Bourla on FDA official Vinay Prasad: 'We have a problem with the leadership of CBER'

Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz

Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Yahoo Finance

Pfizer Arbitration Gag Provision Is Lawful, Labor Board Rules - Bloomberg Law News

New Additions for 2026

Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment - TipRanks

FDA Grants Full Approval to Pfizer’s Braftovi Combo Regimen for Colon Cancer - New Jersey Business & Industry Association

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations - Fierce Biotech

Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28 - 富途牛牛

A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge - Yahoo Finance

What do you think about ABUS??

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient (NYSE:PFE) - Seeking Alpha

Pfizer rare-disease leader moves to drone-safety firm ParaZero - Stock Titan

Pfizer Inc. $PFE Shares Sold by Mcdonald Partners LLC - MarketBeat

Griffith & Werner Inc. Makes New Investment in Pfizer Inc. $PFE - MarketBeat

Pfizer CEO lashes out at FDA vaccine chief - medwatch.com

GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities

Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE - MarketBeat

Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Finviz

Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Yahoo Finance

ABUS Settlement From Lawsuit with Moderna!

Pfizer (NYSE:PFE) Shares Down 2.4% - Here's Why - MarketBeat

Pfizer CEO Albert Bourla on FDA official Vinay Prasad: 'We have a problem with the leadership of CBER' - Fierce Pharma

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Does New Oncology Data Shift The Pipeline-Driven Bull Case For Pfizer (PFE)? - simplywall.st

Pfizer CEO Has ‘A Problem With CBER Leadership’ At US FDA - Citeline News & Insights

Pearl River Summer Internship Housing

Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value - TipRanks

Pfizer CEO On FDA Vaccines Decisions: ‘We Have A Problem With CBER Leadership’ - Citeline News & Insights

Pfizer stock: Mixed technicals and dividend focus drive a sharp downside move - Traders Union

Pfizer's Quiet Cash Comeback (NYSE:PFE) - Seeking Alpha

Pharmalittle: We're reading about an FDA-UniQure feud, Pfizer's 'problem' with the agency, and more - statnews.com

VA Cut Doctors, Nurses; Bhattacharya Urges Measles Vax; Pfizer Voices FDA Concerns - MedPage Today

TTRX take a look at their recent board appointments

Victory Capital Management Inc. Increases Position in Pfizer Inc. $PFE - MarketBeat

How Innovative Diagnostics Are Supporting a Potential Approach to C. difficile - Pfizer

Could This Fuel The Next Surge in Pfizer Stock - Trefis

I took 547 stock recommendations from r/ValueInvesting and had AI grade every single one

South Dakota Investment Council Trims Stock Position in Pfizer Inc. $PFE - MarketBeat

Pfizer-backed Priovant wins FDA priority review for lead asset - Seeking Alpha

Becker Capital Management Inc. Cuts Holdings in Pfizer Inc. $PFE - MarketBeat

AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0 - Yahoo Finance UK

Where Could The Next Breakout for Pfizer Stock Come From - Trefis

Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues - Yahoo Finance

Recon: UniQure pursues path forward for Huntington's treatment despite FDA block; Pfizer CEO critical of FDA’s Prasad - Regulatory Affairs Professionals Society | RAPS

Pfizer CEO flags concerns with US FDA's vaccine leadership - ET Pharma

Pfizer (NYSE:PFE) Trading Down 1.3% - What's Next? - MarketBeat

Pfizer Adds COVID Vaccine Data On Pregnant And Immunocompromised People Showing No AE Links - Citeline News & Insights

Pfizer Options Spot-On: On March 2nd, 103.32K Contracts Were Traded, With 2.67 Million Open Interest - 富途牛牛

Dress Code at Pfizer in Manhattan?

🔔 MARKET CLOSE ────────────────────────────── 📊 INDICES: 🟢 S&P 500: +0.04% (6881.59) 🟢 Nasdaq: +0.36% (22748.86) 🔴 Dow Jones: -0.15% (48904.78) 🟢 Russell 2000: +0.90% (2655.95) 💭 Mixed session. Choppy price action with divergent sector performance. 🔥 HOT STOCKS: 📉 $NV

Argus Research Upgrades Pfizer (PFE) - Nasdaq

Pfizer CEO flags concerns with US FDA's vaccine leadership - Reuters

Pfizer (PFE) Rating Upgraded to Buy by Argus Research | PFE Stoc - GuruFocus

Pfizer at TD Cowen Conference: Strategic Growth Post-COVID - Investing.com

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - The Globe and Mail

Pfizer CEO flags issues with FDA’s vaccine leadership - WTVB

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - AOL.com

Pfizer CEO flags issues with FDA's vaccine leadership - CNBC

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - Yahoo Finance

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell - The Motley Fool

Pfizer CEO flags issues with FDA's vaccine leadership - TradingView

A Look At Pfizer’s (PFE) Valuation After Recent Share Price Momentum And Oncology Growth Hopes - simplywall.st

PFE: Focus on R&D milestones, obesity innovation, and leveraging AI for future industry leadership - TradingView

Is Pfizer Stock an Underrated Healthcare Investment Play? - AOL.com

Pfizer CEO flags concerns with US FDA’s vaccine leadership - PharmaLive

Pfizer CEO flags issues with FDA's vaccine leadership - Yahoo

Pfizer CEO flags concerns with US FDA's vaccine leadership - marketscreener.com

Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - TradingView

Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - Yahoo Finance

Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - Yahoo Finance UK

Noteworthy ETF Inflows: XLV, UNH, TMO, PFE - Nasdaq

Pfizer withdraws Zumrad EMA filing - The Pharma Letter

Pfizer launches Irish science, engineering and manufacturing apprenticeships - Silicon Republic

Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? - Zacks Investment Research

Pfizer (NYSE:PFE) Upgraded by Argus to Buy Rating - MarketBeat

Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer - BioSpace

Pfizer (PFE) Upgraded to Buy by Argus with Positive Growth Outlo - GuruFocus

Apellis adds former Pfizer research chief to board By Investing.com - Investing.com India

Pfizer, Inc. (PFE) Stock Analysis: Navigating the Healthcare Giant’s Growth Potential Amidst a 6.22% Dividend Yield - DirectorsTalk Interviews

Elo Mutual Pension Insurance Co Purchases 110,685 Shares of Pfizer Inc. $PFE - MarketBeat

Fisher Asset Management LLC Purchases 897,786 Shares of Pfizer Inc. $PFE - MarketBeat

Pfizer veteran who led R&D for 16 years joins Apellis board - Stock Titan

Laurel Wealth Advisors LLC Sells 1,110,742 Shares of Pfizer Inc. $PFE - MarketBeat

Antibiotics Market - 4.07% CAGR Forecast for 2026-2031 as Antimicrobial Innovation Strengthens Demand, Says Mordor Intelligence

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits

Why do health insurers generate so little cash compared to pharma?

Eli Lilly Soars, Regencell Speculates, but Pfizer’s 6.4% Yield Makes It the Real Value Play - NAI500

Pfizer Stock (PFE) Opinions on Technical Recovery and Pipeline Progress - Quiver Quantitative

Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need

Pfizer Inc. $PFE Shares Sold by Erste Asset Management GmbH - MarketBeat

Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM - Finviz

Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM - Yahoo Finance

Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM - Yahoo Finance UK

APG Asset Management N.V. Sells 1,033,141 Shares of Pfizer Inc. $PFE - MarketBeat